Good Start Genetics, Inc.
Headquartered in Cambridge, MA, Good Start Genetics is a diagnostic company that has developed a more accurate and comprehensive pre-pregnancy genetic test based on proprietary gene-sequencing technology, designed to replace single-disorder-only tests currently on the market. The company’s CLIA-approved offering launched in early 2012 and allows improved identification of carriers of heritable genetic disorders, enabling physicians to help prospective parents make more knowledgeable medical decisions before conception. www.goodstartgenetics.com
Why Good Start Genetics? — Good Start Genetics is well-positioned to capitalize on the rapidly growing next-generation DNA sequencing field, starting first with its pre-pregnancy carrier test for heritable genetic disorders and eventually to tests for other genetically-related disorders.
Market Opportunity — Genetic disorders impose a significant healthcare burden on society, accounting for 10% of pediatric admissions and 20% of infant mortality. Over 6,000 genetic disorders, each of which affect less than 200,000 Americans, combine to afflict approximately 30M people in the U.S. alone. This high heterogeneity makes diagnosis and treatment difficult and expensive, averaging between $100,000 to several million dollars per child. These costs may be alleviated with pre-pregnancy carrier testing, which may ultimately reduce the cost of healthcare.
Safeguard Board Member — Gary J. Kurtzman, MD
Financial Summary — Safeguard has deployed $10.8 million of capital in Good Start Genetics has a 29% primary ownership position. Co-investors include OrbiMed Advisors, LLC and SV Life Sciences Advisers LLP.
Initial Capital Deployment — September 2010
Sector — Life Sciences, Molecular and Point-of-Care Diagnostics
